Prevention of venous thromboembolism after major orthopedic surgery: Summing up evidence about old and new antithrombotic agents

Journal of Thrombosis and Haemostasis

Volumn 2, Issue 7, 2004, Pages 1055-1057

  Iorio, Alfonso ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN; XIMELAGATRAN;

ACCESS TO INFORMATION; BLEEDING; CLINICAL OBSERVATION; CLINICAL TRIAL; COCHRANE LIBRARY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EUROPE; EVIDENCE BASED MEDICINE; HEALTH CARE ORGANIZATION; HIP SURGERY; HUMAN; KNEE ARTHROPLASTY; KNEE SURGERY; MEDICAL DECISION MAKING; MEDICAL LITERATURE; META ANALYSIS; NORTH AMERICA; NOTE; ORTHOPEDIC SURGERY; PATIENT MONITORING; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; SURGEON; SYSTEMATIC REVIEW; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM;

AZETIDINES; BENZYLAMINES; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; ORTHOPEDIC PROCEDURES; POSTOPERATIVE COMPLICATIONS; THERAPEUTIC EQUIVALENCY; THROMBOEMBOLISM; VENOUS THROMBOSIS; VITAMIN K;

EID: 13244268290     PISSN: 15387933     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2004.00753.x     Document Type: Note

References (25)

1. Gross M, Anderson DR, Nagpal S, O'Brien B. Venous thromboembolism prophylaxis after total hip or knee arthromplasty: a survey of Canadian orthopedic surgeons. Can J Surg 1999; 42: 457-61.
2. Iobst CA, Friedman RJ. The role of low molecular weight heparin in total knee arthroplasty 1999. Am J Knee Surg 1999; 12 55-60.
3. Geerts WH, Heit JA, Clagett GP. Prevention of venous thromboembolism. Chest 2001; 199: 132S-175S.
4. Hull RD, Pineo GF, Francis C, Bergqvist D, Fellenius C, Soderberg K, Holmqvist A, Mant M, Dear R, Baylis B, Mah A, Brant R for the North American Trial Investigators. Low-molecular weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients. Arch Intern Med 2000; 160: 2199-207.
5. Mismetti P, Laporte S, Zufferey P, Epinat M, Decousus H, Cucherat M. Prevention of venous thromboembolism in orthopaedic surgery with vitamin K antagonists: a meta-analysis. J Thromb Haemost 2004; 2: 1058-70.
6. Colwell CW, Collins DK, Paulson R, McCutchen JW, Bigler GT, Lutz S, Hardwick ME. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am 1999; 81-A: 932-40.
7. Fitzgerald RH, Spiro TE, Trowbridge AA, Gardiner Jr GA, Whitsett TL, O'Connell MB, Ohar JA, Young TR, for the Enoxaparin Clinical Trial Group. Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel group comparison of enoxaparin and warfarin. J Bone Joint Surg Am 2001; 83-A: 900-6.
8. Samama CM, Vray M, Barré J, Fiessinger JN, Rosencher N, Lecompte T, Potron G, Basile J, Hull R, Desmichels D for the SACRE study. Extended venous thromboembolism prophylaxis after total hip replacement. A comparison of low-molecular-weight heparin with oral anticoagulant. Arch Intern Med 2002; 162: 2191-6.
9. Clarke M, Oxman AD. Cochrane Reviewers' Handbook 4.0. In: The Cochrane Library, Issue 1. Oxford: Update Software, 2000.
10. Cook DJ, Mulrow CD. Systematic reviews: synthesis of best evidence for health care decisions. Philadelphia: American College of Physicians, 2001; 5-12.
11. Sterne JAC, Egger M, Smith GD. Investigating and dealing with publication and other biases. In: Egger M, Altman DG, Smith GD, eds. Systematic Reviews in Health Care. Meta-Analysis in Context. London: BMJ Publishing Groups, 2001; 189-209.
12. Francis CW, Davidson BL, Berkowitz SD, Lotke PA, Ginsberg JS, Lieberman JR, Webster AK, Whipple JP, Peters GR, Colwell CW Jr. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind trial. Ann Intern Med 2002; 137: 648-55.
13. Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, Peters GR, Roth AW, McElhattan J, Colwell CW Jr, the EXULT A SG. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003; 349: 1703-12.
14. Colwell CW, Berkowitz SD, Davidson BL, Lotke PA, Ginsberg JS, Lieberman JR, Neubauer J, Mcelhattan JL, Peters GR, Francis CW. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb Haemost 2003; 1: 2119-30.
15. Erikkson UG, Johansson L, Frison L, Bredberg U, Gustafsson D. Single and repeated oral dosing of H 376/95, a prodrug of the direct thrombin inhibitor melagatran, to young healthy male subjects. Blood 1999; 94: 26a.
16. Klement P, Carlsson S, Rak J, Liao P, Vlasin M, Stafford A, Johnston M, Weitz JI. The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model. J Thromb Haemost 2003; 1: 587-94.
17. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Lassen MR, Mouret P, Rosencher N, Kalebo P, Panfilov S, Eskilson C, Andersson M. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 2003; 1 2490-6.
18. Mismetti P. Prevention of venous thromboembolism after major orthopedic surgery: 'new' clinical trials for new antithrombotic agents. J Thromb Haemost 2003; 1: 2474-6.
19. Sarich TC, Osende JI, Eriksson UG, Fager GB, Eriksson-Lepkowska M, Ohlsson L, Carlsson S, Wahlander K, Gustafsson D, Badimon JJ. Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r-hirudin in a human 'ex vivo' model of arterial thrombosis. J Thromb Haemost 2003; 1: 999-1004.
20. Eriksson H, Wahlander K, Gustafsson D, Welin L, Frison L, Schulman S. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost 2003; 1: 41-7.
21. Adams TE, Everse SJ, Mann KG. Predicting the pharmacology of thrombin inhibitors. J Thromb Haemost 2003; 1: 1024-7.
22. Schulman S. Unresolved issues in anticoagulant therapy. J Thromb Haemost 2003; 1: 1464-70.
23. Cucherat M, Boissel JP, Leizorovicz A, Haugh MC. Easy MA: a program for the meta-analysis of clinical trials. Comput Meth Programs Biomed 1997; 53: 187-90.
24. Eriksson BI, Berquist D, Kalebo P, Dahl OE, Lindbratt S, Bylock A, Frison L, Eriksson UG, Welin L, Gustafsson D. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002; 360: 1441-47.
25. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Mouret P, Rosencher N, Eskilson C, Nylander I, Frison L, Ogren M, on behalf of the METHRO III study Group. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. The METHRO III study. Thromb Haemost 2003; 89: 288-96.